Authors: Philip Conaghan, Stanley Cohen, Gerd Burmester, Eduardo Mysler, Peter Nash, Yoshiya Tanaka, William Rigby, Jayeshkumar Patel, Tim Shaw, Keith A.

Martin Krusche and Gerd Burmester discuss the potential for machine learning in the treatment of rheumatic diseases, including identification of clinical subgroups and prediction of response to therapy.

Martin Krusche and Gerd Burmester discuss the potential for machine learning in the treatment of rheumatic diseases, including identification of clinical subgroups and prediction of response to therapy.

“Almost two-thirds of patients who tapered discontinued glucocorticoid without flare and maintained low disease activity,” reported Gerd Burmester (Charité-Universitätsmedizin Berlin, Germany).

Presenter : Gerd-Rüdiger Burmester, Charité-Universitätsmedizin Berlin, Germany.

The trial included 259 patients treated with glucocorticoids at a prednisone-equivalent dose of 5– 15 mg/day for 24 weeks or more, Gerd Burmester (Charité-Universitätsmedizin Berlin, Germany) told delegates at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Lead investigator Gerd Burmester, from Charité–Universitätsmedizin in Berlin, Germany, told delegates that the 221 patients treated with upadacitinib 15 mg and the 219 patients given the 30 mg dose were significantly more likely to achieve an ACR20 response at week 12 than the 221 patients in the placebo arm, with corresponding rates of 63.8% and 66.2% versus 35.7%.

Previous studies of mavrilimumab, a monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM–CSF) receptor alpha, “evaluated treatment for ≤ 24 weeks; here we have shown that long-term mavrilimumab treatment generated safety data comparable with the phase IIb qualifying studies [EARTH EXPLORER 1 and 2],” report researcher Gerd Burmester (Charité–University Medicine Berlin, Germany) and colleagues.

Previous analysis at the 1-year timepoint showed that rates of remission were significantly higher among patients taking tocilizumab treatment compared with methotrexate monotherapy, report study author Gerd Burmester (Charité – Universitätsmedizin Berlin, Germany) and colleagues.